Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 19, 2018

Cannabinoids determination in bronchoalveolar lavages of cannabis smokers with lung disease

  • Maria Concetta Rotolo , Manuela Pellegrini , Paola Martucci , Raffaela Giacobbe , Angela De Palma , Roberta Pacifici , Simona Pichini , Francesco Paolo Busardò EMAIL logo and Mario Bisconti

Abstract

Background

Cannabis smoke affects the lungs similarly to tobacco smoke, causing symptoms such as increased cough, sputum, hyperinflation and chronic bronchitis. Chronic use can also cause serious lung diseases and airway obstruction. We developed and validated a method for the identification and quantification of cannabinol (CBN), cannabidiol (CBD), Δ-9-tetrahydrocannabinol (THC) and its metabolites 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC (THC-COOH) in bronchoalveolar lavages (BALs) from hospitalized former or current tobacco smoking patients with lung disease and a long history of cannabis consumption and limited current tobacco use.

Methods

For the extraction of cannabinoids from BALs, a 1 mL sample was added with 300 µL of 0.1 N NaOH and 3 mL of hexane/ethyl acetate (9:1). The solvent was then evaporated to dryness. Trimethylsilyl derivatives were prepared and then analyzed by gas chromatography/mass spectrometry.

Results

The method was linear for the analytes under investigation with coefficients of determination of at least 0.99. Absolute analytical recovery was always better than 80%, imprecision and inaccuracy was always under 15%. Six cases out of 15 were positive for THC, CBN and CBD. In two BALs samples, the presence of 11-OH-THC was also measured while THC-COOH was not detected. In the six positive cases, the last cannabis smoking occurred in the previous 2–14 days.

Conclusions

This is the first time that cannabinoids have been detected in BALs, demonstrating the presence of a drug with its metabolites in a target organ of consumers who present with a lung disease. This occurrence let us hypothesize a role of cannabinoids in the development of the disease and prompted an investigation on possible associations between cannabis smoking and clinical outcomes in patients with lung disease and eventually evaluate a cytotoxic effect of cannabinoids themselves.


Corresponding author: Prof. Francesco Paolo Busardò, MD, MSc, DipFMS, PhD, Associate Professor of Forensic Toxicology and Legal Medicine, Department of Legal Medicine, Università Politecnica delle Marche, Ancona, Italy

Acknowledgments

The authors thank Michele Sciotti, Simonetta di Carlo and Antonella Bacosi for technical assistance.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. World Health Organization – management of substance abuse. http://www.who.int/substance_abuse/facts/cannabis/en/. Accessed: 21 Apr 2018.Search in Google Scholar

2. Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardò FP, Pichini S. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med 2017;55:1555–63.10.1515/cclm-2016-1060Search in Google Scholar PubMed

3. Pacifici R, Marchei E, Salvatore F, Guandalini L, Busardò FP, Pichini S. Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med 2018;56:94–6.10.1515/cclm-2017-0758Search in Google Scholar PubMed

4. United Nations Office on Drugs and Crime. World drug report 2012. http://www.unodc.org/unodc/en/data-and-analysis/WDR-2012.html Accessed: 19 March 2018.Search in Google Scholar

5. Ribeiro LI, Ind PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Prim Care Respir Med 2016;26:16071.10.1038/npjpcrm.2016.71Search in Google Scholar PubMed PubMed Central

6. Tashkin DP, Shapiro BJ, Lee YE, Harper CE. Subacute effects of heavy marijuana smoking on pulmonary function in healthy men. N Engl J Med 1976;294:125–9.10.1056/NEJM197601152940302Search in Google Scholar PubMed

7. Substance Abuse and Mental Health Services Administration (SAMHSA). National Household Survey on Drug Abuse, 1998. 2nd ICPSR version. Research Triangle Park (NC): Research Triangle Institute, Inter-university Consortium for Political and Social Research; 2000. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf. Accessed: 19 March 2018.Search in Google Scholar

8. Sparacino CM, Hyldburg PA, Hughes TJ. Chemical and biological analysis of marijuana smoke condensate. NIDA Res Monogr 1990;99:121–40.10.1037/e496372006-009Search in Google Scholar

9. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007;167:221–8.10.1001/archinte.167.3.221Search in Google Scholar PubMed PubMed Central

10. Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185:1004–14.10.1164/rccm.201202-0320STSearch in Google Scholar PubMed

11. Wille SM, Coucke W, De Baere T, Peters FT. Update of standard practices for new method validation in forensic toxicology. Curr Pharm Des 2017;23:5442–54.10.2174/1381612823666170714154444Search in Google Scholar PubMed

12. Peters FT, Wissenbach DK, Busardo FP, Marchei E, Pichini S. Method development in forensic toxicology. Curr Pharm Des 2017;23:5455–67.10.2174/1381612823666170622113331Search in Google Scholar PubMed

13. Pantano F, Brauneis S, Forneris A, Pacifici R, Marinelli E, Kyriakou C, et al. Determination of oxycodone and its major metabolites noroxycodone and oxymorphone by ultra-high-performance liquid chromatography tandem mass spectrometry in plasma and urine: application to real cases. Clin Chem Lab Med 2017;55:1324–31.10.1515/cclm-2016-0990Search in Google Scholar PubMed

14. Maertens RM, White PA, Williams A, Yauk CL. A global toxicogenomic analysis investigating the mechanistic differences between tobacco and marijuana smoke condensates in vitro. Toxicol 2013;308:60–73.10.1016/j.tox.2013.03.008Search in Google Scholar

15. Sarafian TA, Kouyoumjian S, Tashkin D, Roth MD. Synergistic cytotoxicity of 9-tetrahydrocannabinol and butylated hydroxyanisole. Toxicol Lett 2002;133:171–9.10.1016/S0378-4274(02)00134-0Search in Google Scholar

16. Fabritius M, Chtioui H, Battistella G, Annoni JM, Dao K, Favrat B, et al. Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. Anal Bioanal Chem 2013;405:9791–803.10.1007/s00216-013-7412-1Search in Google Scholar PubMed

Received: 2018-04-23
Accepted: 2018-08-26
Published Online: 2018-09-19
Published in Print: 2019-03-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 1.3.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2018-0426/html
Scroll to top button